Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc (PRGO) on July 6, 2021. The filing reports the completion of a material asset disposition previously announced in March 2021.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of the Generic Rx Pharmaceuticals business (the "Business").
- Buyer: Padagis LLC (f/k/a Vestas Pharma LLC), an affiliate of Altaris Capital Partners, LLC.
- Aggregate Consideration: $1.55 billion, subject to customary adjustments for cash, debt, working capital, and transaction expenses.
- Reimbursements: The purchase price includes approximately $53 million in reimbursements to be delivered in cash by the Buyer.
- Pro Forma Information: Unaudited pro forma condensed financial information giving effect to the transaction is included in Exhibit 99.1.
Material Changes
The primary material change is the divestiture of the Generic Rx Pharmaceuticals business. On July 6, 2021, the Company entered into an Amendment to the original Stock and Asset Purchase Agreement to address tax, employee benefits, cash management, shared systems, and third-party consent matters.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected benefits of the sale. Management notes risks related to the success of the transaction, including the ability to achieve expected benefits and potential costs or liabilities that may exceed estimates. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments for cash, debt, and working capital.
- Review the Unaudited Pro Forma Condensed Financial Information (Exhibit 99.1) to understand the impact on the Company's remaining financial position.
- Examine the Amendment to the Stock and Asset Purchase Agreement (Exhibit 10.2) for details on retained liabilities or ongoing obligations.
- Confirm the status of third-party consents and shared systems transitions mentioned in the Amendment.